There are currently 15 active clinical trials seeking participants for Hepatic Impairment research studies. The states with the highest number of trials for Autism participants are Florida, Texas, California and Minnesota.
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
NCT06052566
Recruiting
The purpose of this study is to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2024
Locations: Clinical Pharmacology of Miami ( Site 0005), Miami, Florida +2 locations
Conditions: Non-alcoholic Steatohepatitis, Hepatic Impairment
Register for Updates
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
NCT05919069
Recruiting
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/12/2024
Locations: Research Site, Rialto, California +2 locations
Conditions: Hepatic Impairment
Register for Updates
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
NCT05935033
Recruiting
The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/05/2024
Locations: Miami, Florida, Miami, Florida +2 locations
Conditions: Hepatic Impairment
Register for Updates
A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
NCT04154774
Recruiting
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relative to participants with normal hepatic function.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
03/26/2024
Locations: Homestead Associates in Research, Inc, Homestead, Florida +3 locations
Conditions: Hepatic Impairment
Register for Updates
Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
NCT05552183
Recruiting
This is a Phase 1 study designed to assess the effect of hepatic insufficiency on the PK of pacritinib by study of 14-day BID dosing of pacritinib in subjects with moderate and severe hepatic impairment compared to healthy matched control subjects with normal liver function. Safety and tolerability of multiple day dosing of pacritinib in the subject populations will also be evaluated.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/15/2024
Locations: Site 2, Orlando, Florida +1 locations
Conditions: Hepatic Impairment
Register for Updates
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
NCT05751759
Recruiting
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/12/2024
Locations: Research Site, Rialto, California +4 locations
Conditions: Hepatic Impairment
Register for Updates
DZD9008 PK Study in Hepatic Impairment Subjects
NCT06084104
Recruiting
This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/29/2024
Locations: Orlando Clinical Research Center, Orlando, Florida +1 locations
Conditions: Hepatic Impairment
Register for Updates
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
NCT04241835
Recruiting
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function. An advanced malignancy is a cancer that has recurred (come back) after prior treatment or hasn't controlled with treatment. The trial will also study th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois +12 locations
Conditions: Hepatic Impairment, Advanced Malignant Solid Tumor
Register for Updates
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
NCT05724693
Recruiting
To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/01/2024
Locations: Atea Study Site Orlando Clinical Research Center, Orlando, Florida
Conditions: Healthy Volunteer, Hepatic Impairment
Register for Updates
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
NCT04950764
Recruiting
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/26/2024
Locations: The Institute of Liver Health dba Arizona Liver Health, Chandler, Arizona +17 locations
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Register for Updates
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
NCT06048302
Recruiting
To investigate the safety and pharmacokinetics in patients with moderate hepatic impairment compared to healthy participants after a single oral dose of obicetrapib (10 mg).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/20/2024
Locations: Nucleus Network, Saint Paul, Minnesota +1 locations
Conditions: Hepatic Impairment, Healthy
Register for Updates
A Study of TAK-279 in Adults With or Without Liver Damage
NCT05976321
Recruiting
The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to participants without liver problems. Other aims are to check for side effects from TAK-279 and to learn how well participants tolerate 1 dose of TAK-279. The participants will need to stay at the clinic for 11 days.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: University of Miami, Miami, Florida +3 locations
Conditions: Hepatic Impairment, Healthy Volunteers
Register for Updates